Form 3: Delphi discloses indirect stakes in Biofrontera Inc. including convertible preferred
Rhea-AI Filing Summary
Delphi Unternehmensberatung AG reported an initial beneficial ownership statement for Biofrontera Inc. (BFRI). The filing discloses 400,000 common shares held indirectly by Biofrontera AG and 58,884 common shares held indirectly by Deutsche Balaton Aktiengesellschaft. It also reports convertible preferred stock representing 4,831,172 underlying common shares held indirectly by Biofrontera AG, convertible at $0.6249 with a 19.99% ownership cap on conversion.
Positive
- Substantial indirect position disclosed: Delphi and affiliates collectively hold approximately 62.2% of Biofrontera AG voting stock, indicating consolidated control at that level.
- Convertible preferred detailed: The convertible preferred maps to 4,831,172 underlying common shares with a clear $0.6249 conversion price and a 19.99% ownership cap, providing transparency on potential dilution.
Negative
- Beneficial ownership disclaimers: The reporting person disclaims direct beneficial ownership, limiting clarity on economic/control exposure beyond stated percentages.
- Conversion restriction: The 19.99% cap on conversion limits immediate conversion flexibility and could complicate any attempt to convert all preferred shares into common.
Insights
TL;DR: Reporting shows significant indirect holdings and layered ownership that imply control influence over Biofrontera AG's voting stock.
The report documents that Delphi Unternehmensberatung AG holds securities indirectly through Biofronfera AG and Deutsche Balaton Aktiengesellschaft. The filing states Delphi and affiliates collectively hold ~62.2% of Biofrontera AG's voting stock, which may confer effective control over decisions at that entity and, by extension, influence over the issuer through indirect ownership. The disclaimer limits admission of beneficial ownership but does not negate the disclosed ownership structure.
TL;DR: Holdings include ~4.83M underlying shares via convertible preferred; conversion capped to avoid >19.99% ownership.
The convertible preferred reported is exercisable at $0.6249 per share and corresponds to 4,831,172 common shares if converted, subject to a 19.99% ownership limitation. This cap restricts immediate dilution risk from a full conversion into a single holder exceeding the threshold. The layered indirect ownership through majority interests in intermediate entities is disclosed plainly without further transactional detail.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series D Convertible Preferred Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The reported shares are held directly by Biofrontera AG. The Reporting Person and its affiliates collectively hold approximately 62.2% of the outstanding voting stock of Biofrontera AG and therefore may be deemed to beneficially own the shares owned by Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The reported shares are held directly by Deutsche Balaton Aktiengesellschaft. The Reporting Person owns a majority interest in VV Beteiligungen Aktiengesellschaft, which owns a majority interest in Deutsche Balaton Aktiengesellschaft. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The convertible preferred stock is convertible at any time at the holder's option, subject to a limitation that prevents the holder and its affiliates from beneficially owning more than 19.99% of the outstanding common stock upon conversion. The preferred stock has no expiration date.
